Company intelligence / Profile preview

Symphony Therapeutics

Bedford, Massachusetts, United Statessymphonytx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Symphony Therapeutics develops novel nano drug delivery platforms—NanoM Wafer™ and OcuSurf™—with a lead program focused on a Lubricating Ocular Bandage for dry eye. The company’s technology enables sustained release of various therapeutic modalities. Clinical results are pending as programs are at preclinical or early clinical stages.

Therapeutic areas: Ophthalmology
Modalities: Small moleculesProteinsPeptidesNucleic acids
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

OcuHeal UV-400+

Pre-clinical

Indications: Ophthalmic disorders

Partnerships

Open to licensing collaborations for additional applications in ophthalmology, urology, and intranasal routes; no specific partners named yet.

Beyond the preview

Go deeper on Symphony Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symphony Therapeutics.

Explore the full profile